A recent Harvard study has discovered that nearly half of individuals taking GLP-1 medications have reported a decrease in their alcohol consumption. The study, published in the journal JAMA Psychiatry, investigated an unexpected side effect of GLP-1 medications, which are commonly used to treat diabetes and obesity. The researchers found that the reduction in alcohol consumption was more pronounced among those who were at risk of unhealthy drinking habits. The study was conducted by a team of researchers from Harvard Medical School, McLean Hospital, Brown, Duke, and Brandeis universities, and the RAND Corporation. The findings suggest that GLP-1 medications may have a positive impact on reducing alcohol consumption, particularly among those who are at risk of developing unhealthy drinking habits. This is an important finding, as it highlights the potential benefits of using GLP-1 medications beyond their primary use in treating diabetes and obesity. The study's results also underscore the need for further research into the relationship between GLP-1 medications and alcohol consumption. The researchers hope that their findings will contribute to the development of more effective treatments for alcohol use disorder. The study's lead author, Haiden Huskamp, noted that the use of anti-abuse medications for alcohol use disorder is still relatively low, with only 3-5% of those with a past alcohol abuse disorder reporting use of these medications. The study's findings have important implications for the treatment of alcohol use disorder and highlight the need for increased awareness and education about the availability and effectiveness of evidence-based treatments.